- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02380937
Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking
Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking: Pilot Study Using a Combination Imricor and Philips Interventional System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An objective of the study is to perform the entire ablation procedure from subject preparation through confirmation of bidirectional conduction block entirely under magnetic resonance guidance. However, at the investigator's discretion, the preparation of the subject may occur in a conventional electrophysiology laboratory followed by transferring the patient to the magnetic resonance suite for the ablation procedure. Additionally, if bidirectional conduction block is not achieved within 90 minutes from the initial catheter placement, the subject may be transferred from the magnetic resonance suite to a conventional electrophysiology lab to complete the procedure. Clinical success is bidirectional conduction block regardless of the environment within which the ablation occurs.
The study will be conducted at a single center, Herzzentrum Leipzig University Hospital, in Germany, and a maximum of 30 subjects meeting inclusion/exclusion criteria will participate in the study. This study requires the use of investigational products from two independent manufacturers: Imricor and Philips. Imricor has developed the ablation catheter with related accessories, introducers, and recording system. Philips has developed an image guidance and mapping system that is compatible with the Imricor products. The Vision Ablation Catheter will be used in conjunction with the following investigational products: Vision Ablation Catheter Cable Set (accessory sterile cable), Vision Hemostasis Introducer, Vision Dual-Deflect Sheath, Horizon recording system, and the interventional MRI Suite (iSuite) image guidance and mapping system. With the exception of iSuite, which is manufactured by Philips, Imricor will provide all investigational devices used in the study. Each procedure will utilize the following two single-use products: two Vision Ablation Catheters and an accessory Catheter Cable set. At the discretion of the investigator, Vision Hemostasis Introducers may be used for femoral access and a Vision Dual- Deflect Sheath and may be used in conjunction with the Vision Ablation Catheter Cable Set. Ablation for the treatment of arrhythmia is an inherently complex procedure. Use of the investigational products listed above under magnetic resonance guidance is a new approach to performing the interventional electrophysiology procedure. The study population will consist of adult patients requiring ablation for type I atrial flutter.
Study subjects will require a follow-up visit or telephone call at 7 days post procedure.
Accordingly, the expected total study duration is approximately six months with study start planned for October 2014.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leipzig, Germany, 04289
- Heart Center Leipzig
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- First time indication for type I atrial flutter ablation
- Age 18 or above
- Patients willing and able (mentally and physically capable per physician's discretion) to understand the investigational nature, potential risks and benefits of the study and able to provide written informed consent to participate in the study and agree to comply with follow-up visits and evaluation
- Patients able to receive anticoagulation therapy to achieve adequate anticoagulation
Exclusion Criteria:
- Contraindication for MRI diagnostic exam
- A cardiac ablation or cardiac surgery within 90 days prior to enrollment
- Documented intracardiac thrombus, tumor, bleeding, clotting or other abnormality that precludes catheter introduction and placement
- Myocardial infarction within 60 days prior to enrollment
- Current unstable angina
- History of cerebrovascular event (within 180 days prior to enrollment)
- Patients with an ejection fraction less than or equal to 30% within 90 day prior to enrollment
- Permanent leads in or through the right atrium
- Clinically significant structural heart disease (including tricuspid valve regurgitation, tricuspid valve stenosis or other congenital heart disease) that would preclude catheter introduction and placement, as determined by the Investigator
- Uncompensated congestive heart failure (NYHA Class III or IV)
- Arrhythmia is secondary to electrolyte imbalance, thyroid disease, or other
- reversible or non-cardiovascular cause
- Known sensitivity to heparin or warfarin
- Active or systemic infection
- Any other significant uncontrolled or unstable medical condition (including but not limited to hypertension and diabetes)
- Women who are pregnant or plan to become pregnant within the course of their participation in the investigation or who are breastfeeding
- Life expectancy of less than 12 months
- Patients with prosthetic valves
- Contraindicated for transfemoral venous access
- Older than 75 years
- Current enrollment in any other clinical investigation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ablation for typical atrial flutter
This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
|
ablation for typical atrial flutter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of serious adverse events
Time Frame: 1 day
|
To provide scientific evidence that the Vision Ablation Catheter is safe as measured by the incidence of device and procedure related serious adverse events (SAEs).
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with successful ablation
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerhard Hindricks, Professor, Heart Center Leipzig
Publications and helpful links
General Publications
- Sommer P, Grothoff M, Eitel C, Gaspar T, Piorkowski C, Gutberlet M, Hindricks G. Feasibility of real-time magnetic resonance imaging-guided electrophysiology studies in humans. Europace. 2013 Jan;15(1):101-8. doi: 10.1093/europace/eus230. Epub 2012 Jul 31.
- Eitel C, Hindricks G, Grothoff M, Gutberlet M, Sommer P. Catheter ablation guided by real-time MRI. Curr Cardiol Rep. 2014 Aug;16(8):511. doi: 10.1007/s11886-014-0511-6.
- Piorkowski C, Grothoff M, Gaspar T, Eitel C, Sommer P, Huo Y, John S, Gutberlet M, Hindricks G. Cavotricuspid isthmus ablation guided by real-time magnetic resonance imaging. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):e7-10. doi: 10.1161/CIRCEP.112.973719. No abstract available.
- Hilbert S, Sommer P, Gutberlet M, Gaspar T, Foldyna B, Piorkowski C, Weiss S, Lloyd T, Schnackenburg B, Krueger S, Fleiter C, Paetsch I, Jahnke C, Hindricks G, Grothoff M. Real-time magnetic resonance-guided ablation of typical right atrial flutter using a combination of active catheter tracking and passive catheter visualization in man: initial results from a consecutive patient series. Europace. 2016 Apr;18(4):572-7. doi: 10.1093/europace/euv249. Epub 2015 Aug 27.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 104/14-ff
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Flutter
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
University of PennsylvaniaWithdrawnTypical Atrial Flutter | Risk Factors With Future Development of Atrial FlutterUnited States
-
Angelo BivianoCompleted
-
Kaiser PermanenteActive, not recruitingAtrial Fibrillation and FlutterUnited States
-
Charles University, Czech RepublicCompleted
-
Hospital Universitario Central de AsturiasJohnson & JohnsonUnknown
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
University of ManchesterManchester University NHS Foundation TrustWithdrawn
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
Clinical Trials on ablation for typical atrial flutter
-
University of LeipzigPhilips Healthcare; Heart Center Leipzig - University Hospital; Imricor Medical...TerminatedAtrial FlutterGermany
-
University of LeipzigPhilips Healthcare; Heart Center Leipzig - University Hospital; Imricor Medical...Completed
-
University of CalgaryNot yet recruitingAtrial Flutter | Atrial Flutter Typical | Cavotricuspid Isthmus Dependent Macroreentry TachycardiaCanada
-
University Hospital, RouenTerminated
-
Biosense Webster, Inc.CompletedAtrial FlutterUnited States
-
University Hospital, GenevaUnknownRadiofrequency Ablation | Typical Atrial Flutter | Irrigated CathetersSwitzerland
-
University Hospital, RouenMedtronicCompletedAtrial Fibrillation | Atrial FlutterFrance
-
Stiftung Institut fuer HerzinfarktforschungBoston Scientific CorporationCompleted
-
EPD Solutions, A Philips CompanyTerminated
-
David B. De LurgioBoston Scientific CorporationCompletedAtrial Flutter | Cardiac Arrhythmias | Cardiac Catheter AblationUnited States